 |
Hold (2.33 out of 4)
100th percentile
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Thursday, April 18, 4:39 AM
Slide #265. Trillium Therapeutics Inc. — Preferred Stock Offering
| Company: |
Trillium Therapeutics Inc. (TRIL) |
| Date announced: |
5/25/2017 |
| Shares Offered: |
2,750,000 |
| Date of Pricing: |
5/26/2017 |
| Price Per Share: |
$5.00 |
| Preferred Stock Offering Details: |
Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of its common shares and Series II Non-Voting Convertible First Preferred Shares. The Series II Non-Voting Convertible First Preferred Shares are being offered to investors whose purchase of common shares in the offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company's outstanding common shares following the consummation of the offering. The Company also intends to grant the underwriters a 30-day option to purchase from it up to an additional 15% of the common shares offered in the offering. -updated 5/26- Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of US$5.00 per share and the Series II Non-Voting Convertible First Preferred Shares are being sold at a public offering price of US$5.00 per share. The gross proceeds to the Company from this offering are expected to be approximately US$30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30-day option to purchase from it up to an additional 412,500 common shares on the same terms and conditions. The offering is expected to close on June 1, 2017, subject to the satisfaction of customary closing conditions. |
Trillium Therapeutics is a clinical stage immuno-oncology company developing therapies for the treatment of cancer. Co.'s primary program, TTI-621, is a SIRPaFc fusion protein that consists of the extracellular CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the Fc region of a human immunoglobulin G1 (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Co. is also developing a second SIRPaFc fusion protein, TTI-622, which consists of the extracellular CD47-binding domain of human SIRPa linked to a human immunoglobulin G4 Fc region, which has a decreased ability to engage Fc receptors than an IgG1 Fc.
 Open the TRIL Page at Preferred Stock Channel »
Open the TRIL Page at Preferred Stock Channel (in a new window) »
|
|
Free TRIL Email Alerts:
